Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in RAS-mutant Advanced Biliary Tract Cancer
NCT07908550Phase 2Not yet recruiting
- Sponsor
- National Health Research Institutes
- Start
- Jan 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of daraxonrasib in biliary tract cancer (BTC), sponsored by National Health Research Institutes. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
daraxonrasib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07908550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908550.